A 44% Discount to a Book That Keeps Shrinking

On September 10, BofA Securities cut Crescent Capital BDC (CCAP) from Buy to Neutral and slashed its price target from $13 to $10.25, pointing at the stock's net asset value discount and "credit stress." Shares fell about 3% that day to just under $10.

To a retail investor glancing at the tape, that read looks like an invitation to bargain-hunt, not a reason to pause. CCAP trades at roughly 56 cents for every dollar of stated book value — a 44% discount — and its trailing dividend yield sits near 17%. A lender trading at less than half of net asset value while paying out a double-digit yield is the classic deep-value pitch.

Except the discount is attached to a number that is not standing still.

A discount is only a return if the book holds

A BDC is a lending vehicle that owns a portfolio of loans to mid-sized companies, and it is valued mostly by the fair value of that loan book — its net asset value per share. The entire "discount to NAV" trade is a bet that the book holds, so the market eventually pays closer to its stated worth. That requires the denominator to stop falling.

Crescent's has not stopped. NAV has slid from $19.55 a year ago to $18.27 at the end of March and then $17.82 at the end of June.

The culprit is inside the loan book, not just a choppy market. The pain is concentrated in healthcare credits, where Crescent booked realized losses in the second quarter and net losses in both the first and second quarters. Non-accruals — loans that have stopped paying — eased from 5.7% to 4.8% of debt at cost, and management restructured three loans with only minimal impact on NAV. But the less visible strain moved the other way: the "watchlist" of underperforming-but-not-yet-non-accrual names climbed to 15% of the portfolio.

The cleanest way to see the problem is to stack the last six quarters together. Over that stretch, Crescent earned $2.60 per share of net investment income and simultaneously recognized $2.59 per share of combined realized and unrealized losses. It is cutting a dividend check, but the book is giving back almost exactly what it earns to do it.

The big yield is the trap if the income engine keeps shrinking

Net investment income — the interest and dividends the portfolio generates minus costs — has been drifting down: $0.46 a share a year ago, $0.42 in the prior quarter, $0.36 in the second quarter of 2026. Management cut the base dividend to $0.34 a share to line up with the smaller income engine, adding only a small $0.03 special on top. That keeps the headline yield large, but the income barely covers the base payout now, and the trajectory is all one direction: consensus estimates for coming quarters edge down, and revenue ran about 18% below a year earlier.

Now put that shrink next to the valuation, because in this sector the discount only means something in relation to peers. Crescent's price-to-book of roughly 0.56 is the deepest in a set where Ares Capital trades at about book value (roughly 1.0x) with a near-10% yield and Hercules Capital trades above book (about 1.4x) near an 11% yield. Even FS KKR, another deep-discount BDC, sits closer to 0.62x book. The market is not mispricing Crescent versus its group — it is charging a discount for a book in decline, for leverage that has crept to about 1.4x debt-to-equity, above the company's own target range, and for an income stream doing the shrinking.

That is the sector-relative read the whole case turns on: value is the only factor working for Crescent, and value alone is a trap here because growth, profitability, and safety are all still pointing down. Momentum is badly negative — the stock is down roughly 30% this year against a 52-week range of $9.88 to $15.82 — and revisions are drifting lower as NII erodes.

What BofA is really saying

The downgrade matters less for the letter grade than for what it forces investors to stop doing: treating a 44% discount as guaranteed money. BofA's Neutral is a "hold until the book stabilizes" position, not a verdict that Crescent is overvalued — the new $10.25 target is essentially where the stock already sits. The meaningful content is the wait in the middle.

So the honest question is not "is 44% off cheap?" It is "is the book done falling?" Management says Crescent has roughly $200 million of available borrowing capacity and expects portfolio realizations to cut leverage in the second half of 2026. That — plus a flat NAV through Q3 and Q4 — is the evidence that would convert a tempting discount into a real one. Until it arrives, that 17%-looking yield is being paid, in part, out of a shrinking asset base, which is precisely the kind of "cheap" you want someone else to rush toward.